These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 7907955)

  • 21. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study.
    Diana T; Brown RS; Bossowski A; Segni M; Niedziela M; König J; Bossowska A; Ziora K; Hale A; Smith J; Pitz S; Kanitz M; Kahaly GJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1648-55. PubMed ID: 24517152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy.
    Hidaka Y; Tamaki H; Iwatani Y; Tada H; Mitsuda N; Amino N
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):15-20. PubMed ID: 7914152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
    Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
    Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid response, especially to thyrotropin-binding inhibitory immunoglobulins, in euthyroid relatives of patients with Graves' disease: a clinical follow-up.
    Tamai H; Kasagi K; Morita T; Hidaka A; Kuma K; Konishi J; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1990 Jul; 71(1):210-5. PubMed ID: 1973421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study.
    Vos XG; Smit N; Endert E; Tijssen JG; Wiersinga WM
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):311-7. PubMed ID: 18208575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C; Nishikawa M
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):206-15. PubMed ID: 2456230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.
    Kim WB; Chung HK; Park YJ; Park DJ; Lee HK; Cho BY
    Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of thyroid stimulating activities measured by cyclic AMP production, those by radioiodine uptake in FRTL-5 cells and TSH-binding inhibitory activities in patients with hyperthyroid and euthyroid Graves' diseases.
    Kasagi K; Hatabu H; Tokuda Y; Arai K; Iida Y; Konishi J
    Acta Endocrinol (Copenh); 1988 Mar; 117(3):365-72. PubMed ID: 2898192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.
    Ota H; Amino N; Morita S; Kobayashi K; Kubota S; Fukata S; Kamiyama N; Miyauchi A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):41-5. PubMed ID: 17437515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in thyrotropin receptor antibody after subtotal thyroidectomy in Graves' disease: comparison with the degree of lymphocytic infiltration in the thyroid.
    Cho BY; Oh SK; Shong YK; Kim SE; Yoo HY; Lee HK; Koh CS; Min HK
    Autoimmunity; 1990; 8(2):143-7. PubMed ID: 1983330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells.
    Kamijo K; Nagata A; Sato Y
    Endocr J; 1999 Jun; 46(3):397-403. PubMed ID: 10503992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
    Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.
    Sarić Matutinović M; Diana T; Nedeljković Beleslin B; Ćirić J; Žarković M; Kahaly GJ; Ignjatović S
    J Endocrinol Invest; 2022 Jan; 45(1):189-197. PubMed ID: 34324163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Studies on the radioreceptor assay of TSH: the properties of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease (author's transl)].
    Endo K
    Nihon Naibunpi Gakkai Zasshi; 1979 Oct; 55(10):1261-74. PubMed ID: 228998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
    Ochi Y; Kajita Y; Hamazu M; Nagata A
    Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease.
    Macchia E; Fenzi GF; Monzani F; Lippi F; Vitti P; Grasso L; Bartalena L; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):175-82. PubMed ID: 6118213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of thyroid stimulating antibodies and TSH binding inhibitor immunoglobulins in patients with thyroid diseases and its clinical applications].
    Liu C; Yin F; Zhang Z
    Zhonghua Nei Ke Za Zhi; 1995 Feb; 34(2):105-7. PubMed ID: 7796654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.
    Michelangeli VP; Poon C; Topliss DJ; Colman PG
    Thyroid; 1995 Jun; 5(3):171-6. PubMed ID: 7580264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.